Alnylam announces positive outcome of fda advisory committee meeting on patisiran for the treatment of the cardiomyopathy of attr amyloidosis

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced the positive outcome of the u.s. food and drug administration's (fda) cardiovascular and renal drugs advisory committee (crdac) meeting to discuss the supplemental new drug application (snda) for patisiran, an investigational rnai therapeutic in development for the treatment of the cardiomyopathy of transthyretin-mediated (attr) amyloidosis. the crdac voted 9:3.
ALNY Ratings Summary
ALNY Quant Ranking